Overview
Quanta Therapeutics develops oral, allosteric small molecule inhibitors targeting KRAS mutations like G12D and G12V in RAS-driven cancers including pancreatic, colorectal, lung, and endometrial. Their pipeline features Phase 1 candidates QTX3034, QTX3544, and QTX3046, leveraging a proprietary Second Harmonic Generation platform for protein conformational detection. The company advances best-in-class therapies to expand treatment options beyond G12C mutations.
Frequently asked questions
- What KRAS mutations does Quanta target?
- Quanta targets KRAS G12D and G12V mutations primarily, with multi-KRAS inhibitors like QTX3034 (G12D-preferring) and QTX3544 (G12V-preferring), addressing cancers such as pancreatic, colorectal, lung, and endometrial.
- What is the clinical stage of Quanta's pipeline?
- QTX3034 and QTX3544 are in Phase 1 clinical trials, with QTX3034 advancing to dose expansion in KRAS G12D-mutant cancers based on favorable safety and efficacy data; QTX3046 is also progressing.
- What technology powers Quanta's drug discovery?
- Quanta uses a Second Harmonic Generation (SHG) platform, an optical technology that detects subtle protein conformational changes to identify allosteric modulators of RAS signaling complexes.